Impact of metabolic syndrome on clinical and angiographic outcome after sirolimus-eluting stent implantation

Coronary Artery Disease

Volumn 18, Issue 8, 2007, Pages 601-606

  Stellbrink, Ekaterina ^a   Schröder, Jörg ^a   Grawe, Armin ^a   Goebbels, Rainer ^a   Blindt, Rüdiger ^a   Kelm, Malte ^a   Hoffmann, Rainer ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Diabetes; Drugs; Metabolic syndrome; Restenosis; Stents

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN;

ADULT; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVASCULARIZATION; ST SEGMENT ELEVATION;

AGED; CORONARY ANGIOGRAPHY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SIROLIMUS; STENTS;

EID: 40349092912     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282f09066     Document Type: Article

References (25)

1. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109:714-721.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
3. Alexander CM. The coming of age of the metabolic syndrome. Diabetes Care 2003; 26:3180-3181.
4. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004; 27:990-994.
5. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32:584-589.
6. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients. J Am Coll Cardiol 2002; 36:731-738.
7. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in diabetic patients. Heart 2006; 92:1119-1124.
8. Moussa I, Leon MB, Baim DS. Impact of sirolimus eluting stents on outcome in diabetic patients. A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109:2273-2278.
9. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112:2735-2752.
10. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311:158-161.
11. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107:391-397.
12. Scheen AJ, Warzée F, Legrand VMG. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 2004; 25:2167-2168.
13. Lemos PA, Serruys PW, van Domburg RT. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'Real World'. The Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004; 109:190-195.
14. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al., ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353:663-670.
15. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, et al. Metabolic syndrome and early-onset coronary artery disease. J Am Coll Cardiol 2006; 48:1800-1807.
16. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 2005; 289:H228-H236.
17. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res 2005; 97:725-733.
18. Piatti PM, Di Mario C, Monti L, Fragasso G, Sgura F, Caumo A, et al. Association of insulin resistance, hyperleptinemia and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108:2074-2081.
19. Radke PW, Voswinkel M, Reith M, Kaiser A, Haager PK, Hanrath P, Hoffmann R. Relation of fasting insulin plasma levels to restenosis after elective coronary stent implantation in patients without diabetes mellitus. Am J Cardiol 2004; 93:639-641.
20. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: intravascular ultrasound studies. J Diabetes Complications 2002; 16:50-55.
21. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, et al.; Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146:351-358.
22. 1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 2003; 92:1282-1286.
23. Rana JS, Monraats PS, Zwinderman AH, de Maat MPM, Kastelein JJP, Doevendans PAF, et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 2005; 28:873-877.
24. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al., West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-1600.
25. Han TS, Williams K, Sattar N, Hunt KJ, Lean ME, Haffner SM. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10:923-931.